Abstract: Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products.

Abstract: The invention is directed to a novel enzymatic analytical membrane, a lateral flow enzymatic detection method, and analytical device incorporating same. The invention is useful for rapidly enzymatically determining the presence of one or more analytes in small volumes of sample. The invention provides an enzymatic analytical membrane for detecting the presence of one or more small-molecule analytes in a biological sample where the membrane comprises a receiving zone; a separation zone and a signal zone, at least one of the zones comprising one or more enzymes for converting the analytes into a form detectable by reaction with a chromogenic agent present in the signal zone and wherein the membrane horizontally receives sample at the receiving zone, and the sample continues via lateral flow through the receiving zone, separation zone and signal zone where a visible color change is formed indicating the presence of the analyte.

Abstract: Methods of activating an apo-peroxidase are provided. The methods include the steps of providing a solution comprising an apo-peroxidase and a heme choline ester, hydrolyzing the heme choline ester with a choline esterase, and converting the apo-peroxidase to active peroxidase. The methods disclosed herein also provide for detecting the presence of an analyte in a sample. The methods include providing a binder capable of specifically binding the analyte wherein the binder is attached to a solid surface, applying the sample to the solid surface under conditions that permit binder-analyte binding, adding a choline esterase-conjugated binder that binds to the analyte, adding an apo-peroxidase, a heme choline ester, a peroxide, and a peroxide-activated signal generator, and detecting the signal produced by the peroxide-activated signal generator. An associated kit and components are also provided.

Abstract: The invention relates to a method for diagnosis and/or diabetic complications and/or risk assessment of pancreatic diabetes, in particular of diabetic sequelae, wherein a determination of the marker procalcitonin (PCT: SEQ ID No. 1) or a partial peptide or fragment thereof or if contained in a marker combination (Panel, Cluster) is carried out on a patient under investigation. The invention further relates to a diagnostic device and a kit for carrying out said method.

Abstract: The present invention provides methods of detecting cancer using biomarkers.

Abstract: The invention provides enzymatic methods for direct determination of percentage of glycated hemoglobin in blood samples without the need of a separated measurement of total hemoglobin content in blood samples. The methods utilizes one or two different types of oxidizing agents which selectively oxidize low-molecular weight reducing substances and high-molecular weight (mainly hemoglobin) reducing substances in blood samples, coupled with enzymatic reactions catalyzed by proteases, fructosyl amino acid oxidase. The amount of hydrogen peroxide generated in the reaction is measured for determination of percentage of glycated hemoglobin in blood samples. The invention provides kits for performing the methods of the invention.

Abstract: The invention relates to methods and kits for detecting thyroid cancer by detecting differences in the expression of genes that are differentially expressed in thyroid cancer cells.

Abstract: The application discloses new biomarkers for hypertensive disorders of pregnancy and particularly preeclampsia; methods for the diagnosis, prediction, prognosis and/or monitoring said disorders based on measuring said biomarkers; and kits and devices for measuring said biomarker and/or performing said methods.

Abstract: Methods of treating disorders such as neurofibromatosis-1 are provided, including methods in which catalytic antioxidants such as metalloporphyrins are administered. Methods of regulating longevity, and methods and systems for screening for modulators of aging or longevity, are also provided. In addition, related transgenic animals are described.

Abstract: Methods of inhibiting S. aureus propagation, and screening for compounds that inhibit S. aureus propagation, are described. A method of inhibiting S. aureus propagation comprises inhibiting ribosomal binding of a specific S. aureus tRNA in the S. aureus by an amount sufficient to inhibit S. aureus protein expression. A method of screening for compounds useful for inhibiting S. aureus propagation comprises contacting a specific S. aureus tRNA to a ribosome that binds that tRNA in the presence of the test compound, and then determining whether the compound inhibits the binding of that tRNA.

Abstract: A method of assaying a glycated protein in a sample with the use of redox reaction, in which highly reliable measurement can be obtained. A sample containing a glycated protein is treated with protease in the presence of a sulfonic acid compound, so that the glycated protein is degraded. The glycated portion of the resultant glycated protein degradation product is reacted with fructosyl amino acid oxidase, and this redox reaction is measured, thereby determining the amount of glycated protein. Sodium lauryl sulfate can be used as the sulfonic acid compound.

Abstract: The present invention relates to methods for the diagnosis of impaired cardiac function/heart disease. The present invention provides a method of diagnosing heart disease in a subject, said method comprising determining the level of CgB or SgII, or fragments thereof, in a body fluid of said subject. Such methods can also be used to determine the clinical severity or prognosis of heart disease in a subject.

Abstract: A method for rapidly detecting the presence of formaldehyde in a urine sample (e.g., urine or a urinary material associated therewith, such as headspace gas located associated with urine) is provided. The method includes contacting the urine sample with a substrate on which is disposed a colorant that is capable of undergoing a detectable color change in the presence of formaldehyde. Without intending to be limited by theory, it is believed that oxidation of the colorant by formaldehyde induces either a shift of the absorption maxima towards the red end of the spectrum (“bathochromic shift”) or towards the blue end of the spectrum (“hypsochromic shift”). The absorption shift provides a color difference that is detectable, either visually or through instrumentation, to indicate the presence of formaldehyde within the urine sample. For example, prior to contact with a urine sample, the colorant may be colorless or it may possess a certain color.

Abstract: A catheter for insertion into a blood vessel, the catheter having a sampling part arranged to capture a blood sample at a plurality of locations along a length of the blood vessel and an apparatus arranged to analyse blood taken from a plurality of locations along the length of the blood vessel and to provide a profile of concentration levels along the length of the blood vessel.

Abstract: A method of measuring HbA1c is provided that, even with a whole blood sample after storage, measurement accuracy substantially equal to a whole blood sample right after collection can be maintained. Whole blood is stored in a presence of a glycolytic inhibitor and protease is added to the stored whole blood sample to cleave hemoglobin in the whole blood sample. Then a glycated part of a hemoglobin fragment thereby obtained is treated with fructosyl amine oxidase. Thereafter, a glycation degree of HbA1c is determined by measuring a redox reaction between the glycated part and the fructosyl amine oxidase. Further, instead of storage of the whole blood in a presence of the glycolytic inhibitor, a strong electrolyte substance such as KCl, K2SO4, KNO, NaCl, Na2SO4, NaNO, MgCl2, MgSO4, Mg(NO)2, etc. is added to the whole blood after storage and a protease treatment is performed in a presence of the strong electrolyte substance.

Abstract: Polymerized conjugates of at least two proteins that have increased sensitivity for detecting proteins in biological assays such as gels and blots, and methods of preparing the conjugates, and a protein assay detection kit using the conjugates. In one embodiment, proteins are polymerized by reacting a carbohydrate group on the protein that has been oxidized with an amine group.

Abstract: Disclosed is a method for determining histaminase (DAO; EC 1.4.3.6) activity in a sample. Said method comprises the following steps: an aqueous solution is supplied which contains a predefined amount of a diamine; the aqueous solution is mixed and incubated with the sample for a given period of time in conditions in which the diamine can be reacted with a DAO possibly present in the sample; the diamine is derivatized; the amount of derivatized diamine is determined; the predefined amount of diamine is compared to the amount of derivatized diamine; and the activity of histaminase possibly present is determined.

Abstract: The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury.

Abstract: Provided is a method for determining whether an individual is likely to be susceptible to radiation pneumonitis from radiation therapy and for developing a treatment based on the determination of susceptibility. The method involves measuring SOD and GPX activity levels. A high SOD or low GPX activity, or a combination thereof, is indicative that the individual is likely to be susceptible to radiation pneumonitis.

Abstract: Methods for determining the efficiency of a therapeutic. In at least one embodiment of a method of determining the efficacy of a therapeutic compound, the method comprises the steps of treating a subject having a disease state with an effective amount of therapeutic compound, harvesting at least one cell from the subject following a treatment with the therapeutic compound, bringing the at least one cell into contact with a stabilizing compound capable of completely or substantially preventing the degradation or inactivation of a diagnostic marker for the disease state, analyzing the at least one stabilized cell for the at least one diagnostic marker, creating a marker profile from at least one result determined from analyzing the at least one stabilized cell, and comparing the marker profile with at least one previous marker profile to determine efficacy of the therapeutic compound on the disease state.

Abstract: Systems and methods for identifying allergies. In at least one embodiment of a system of the present disclosure, the system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for a non-food allergy in a body fluid comprising the diagnostic marker and a detection agent capable of detecting the diagnostic marker.

Abstract: The invention relates to a method for characterizing, in particular for quantifying molecular marker(s) that are intracellularly absorbed from tissues by blood macrophages that are recirculated from the tissues into the circulatory system, wherein the following steps are carried out: application of an agent to whole blood, said agent inhibiting coagulation and/or agglomeration of whole blood; selecting and/or enriching and/or separating blood macrophages or leukocyte populations that contain blood macrophages from whole blood; perforating and/or lysing the selected blood macrophages or leukocyte populations containing the blood macrophages, optionally after previous permeabilization thereof; qualitatively and quantitatively determining non blood macrophage markers, namely molecular markers arising from tissue, after previously perforating and/or lysing the blood macrophages or leukocyte populations containing the blood macrophages, and an apparatus for carrying out the method.

Abstract: Systems and methods for detecting pregnancy. In at least one embodiment of a system of the present disclosure, the system comprises a stabilizing agent useful to completely or substantially prevent degradation or inactivation of a diagnostic marker for pregnancy in a body fluid comprising the diagnostic marker, and a detection agent capable of detecting the diagnostic agent.

Abstract: The present disclosure provides systems for the rapid and sensitive detection of organisms and molecules in samples. Reactants that produce Raman-active products are used in combination with Raman light scattering. The present disclosure can also be used to measure enzyme-kinetics.

Abstract: An aqueous composition which comprises a protein or other biological molecule and also (i) optionally comprises one or more metal ions at a concentration of 0.01 to 20 mM; (ii) comprises excipients which are weak ligands; and (iii) is substantially free of excipients which are medium-strength ligands or strong ligands.

Abstract: The present invention relates to methods and compositions for modifying, isolating, detecting, visualizing, and quantifying citrulline and/or homocitrulline-containing peptides, polypeptides, and proteins using mono- and disubstituted glyoxal derivatives. The invention also provides kits for modifying, isolating, detecting, visualizing, and quantifying the relative amounts of citrulline and/or homocitrulline-containing peptides, polypeptides, or proteins in solutions or samples.

Abstract: The invention is a method for determining the concentration of an analyte in whole blood, wherein the analyte is a component which is contained in the blood, is different from a component occurring only in a red blood cell, and can generate hydrogen peroxide upon the reaction with an oxidase. Whole blood is utilized in the method. The method comprises the steps of hemolyzing the whole blood and detecting hydrogen peroxide generated by the reaction between the analyte and the oxidase. The measurement method can avoid the inhibition of color development by hemoglobin and the interference with the measurement by hemoglobin. Further it can be used for biological tests that are carried out in a household, an individual doctor's clinic or at the bedside of patients without the need for any blood cell separation procedure or the like, because the measurement utilizes whole blood.

Abstract: Methods are provided for simultaneously measuring hematocrit (hct) level and the concentration of a biomarker in a blood specimen. Thus, serum biomarker concentrations can be more accurately measured. The methods are particularly useful for newborn screening programs.

Abstract: A method of detecting a gene including immobilizing a primer for DNA elongation onto an insoluble carrier having on the surface thereof a polymer substance containing a first unit having a phosphorylcholine group and a second unit having a carboxylic acid-derived group having an electron-attractive substituent bound to a carbonyl group; annealing the template DNA fragments or RNA fragments with the primer for DNA elongation, so as to elongate the DNA primer while incorporating therein an enzyme, thereby allowing coloration of a chromogenic reagent by its enzymatic action; and judging whether the DNA fragments or RNA fragments of the gene presents or not, based on the degree of coloration.

Abstract: Subject of the present invention are assays and in vitro methods for the in vitro diagnosis, prognosis and risk stratification of a patient having a primary, non-infectious disease, whereby the level of Procalcitonin (PCT) in a sample of a body fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition.

Abstract: An analytical strip and a detecting method using the analytical strip are provided. The analytical strip includes a substrate having a channel thereon. The channel has a first region, a second region and a third region, which are connected sequentially. A first antibody is localized in the first region. A saccharide and a peroxidase are localized in the first or second region. A second antibody for recognizing a different epitope of an identical antigen with the first antibody is immobilized in the second region. An optical substrate and a substrate reagent including a saccharide oxidase are localized in the third region.

Abstract: A method of covalently bonding a cyclic nitroxide radical compound to a hydrophobic block of a specific hydrophylic-phobic block copolymer, and polymerized cyclic nitroxide radical compound copolymerized in this manner, as well as use of such a compound, for instance, in the medical field are provided. The compound demonstrates long term stability in vivo under reductive environment.

Abstract: The invention is directed to biomarkers for determining the EGFR kinase activity in a subject, and the use thereof for predicting and monitoring therapeutic intervention in cancer patients. Areas of application are the life sciences: biology, biochemistry, biotechnology, medicine and medical technology. The biomarkers are selected from a first group consisting of Amy 1, Apo Al, Carbx, Casp, AFP, ApoM, SAP, Fib-a, Fib-b, Fib-g, ApoE, A2MG, A2MG isoform, Serpin, Clusterin, MHC-fB, SAP isoform, or from a second group consisting of Gpx3, properidin, MUP1, HMW-K, Lifr-p, Orm 1, MBL-A, MBP-C, wherein the biomarkers are regulated by EGF overexpression in a subject.

Abstract: Subject of the present invention are assays and in vitro methods for the in vitro diagnosis, prognosis and risk stratification of a patient having a primary, non-infectious disease, whereby the level of Procalcitonin (PCT) in a sample of a body fluid of the patient is indicative for the risk of the patient to contract a further disease or medical condition.

Abstract: Subject of the present invention are assays and in vitro methods for determining a prognosis for a patient having an acute coronary syndrome, whereby the level of procalcitonin or fragments thereof is measured in a sample obtained from said patient. Said level of procalcitonin or fragments thereof may then be correlated to a predisposition to an adverse outcome of said acute coronary syndrome.

Abstract: A method and apparatus for determining the concentration of an analyte in a sample is provided. This method involves combining enhanced chemiluminescence with microchip capillary electrophoresis or microchip liquid chromatography.

Abstract: The invention provides novel fluorinated resorufin compounds that are of use in a variety of assay formats. Also provided are methods of using the compounds and kits that include a compound of the invention and instructions detailing the use of the compound in one or more assay formats.

Abstract: A diagnostic chewing gum for identifying a risk for diabetes includes a mixture of an enzyme, a conjugated protein of the glucose enzyme, a substrate, and a gum base. The enzyme and the conjugated protein facilitate a conversion of the substrate to produce a detectable signal in the presence of glucose to produce a detectable change in the gum. In use, the gum is chewed, the resulting change in the gum is compared against a chart, and the risk for diabetes is determined from the chart.

Abstract: Method for determining the level of PTX3 protein in a sample of a biological fluid; hybridoma capable of producing a rat anti-PTX3 monoclonal antibody where said hybridoma is selected from the group comprising MNB10 and Pen-3; specific anti-PTX3 rat monoclonal antibody selected from the monoclonal antibodies produced by the hybridomas MNB10 and Pen-3; kit for determining the level of PTX3 protein in a biological fluid wherein the said kit includes a rat anti-PTX3 monoclonal antibody.

Abstract: The present invention relates to identification of tumor suppressor activity of a protein, KLF6 (KLF6), and to related diagnostic and therapeutic compositions and methods. The discovery of this tumor suppressor activity provides screening targets as well, particularly screening for compounds that overcome gene inactivation or alteration.

Abstract: Method for increasing the emission of light from a chemiluminescent reaction including luminol, a peroxidase enzyme, an oxidant and a mediator of electrons through the use of a hypernucleophilic acylation catalyst belonging to the class of 4-aminopyridines. It is also described the use in diagnostic assays of chemiluminescent substrates containing said catalysts.

Abstract: Disclosed herein is a dry fluorescence biosensor strip for rapid detection of a target analyte present in bodily fluids. The dry fluorescence biosensor strip comprises a sample receptacle and a dry detection membrane. The sample receptacle receives a sample of one of the bodily fluids. The dry detection membrane detects presence of the target analyte in the received sample based on fluorescence induced on the dry detection membrane. Fluorescent signals are emitted from the dry detection membrane on induction of fluorescence. A fluorometer quantifies measurable properties of the target analyte based on the emitted fluorescent signals. The dry fluorescence biosensor strip may further comprise a filtration membrane for filtering the received sample. The filtered sample migrates from the filtration membrane to the dry detection membrane. The dry detection membrane may then detect presence of the target analyte in the filtered sample.

Abstract: A reagent is provided for the detection of an exotoxin protein produced by a betahemolytic streptococcus bacteria suspected of being present in a host biological fluid collected from a subject. A kit is provided that is readily usable by an unskilled user and merely requires that an element of the kit be contacted with a biological sample and that element is then subjected to electromagnetic spectral energy. The incident electromagnetic spectral energy then reacts with the exotoxin protein indicator and can be reliably measured by an electromagnetic spectral emission. The emission is measured by a reporting module and is displayed to the user in a form recognized by the user's sensory systems; sight, sound, etc. or a combination thereof.

Abstract: A test agent includes a composite probe having at least one nanoparticle having multiple metal atoms, a directing agent, and an enzyme. The directing agent attaches the probe to a target in a test sample. The test sample and bound probe are then treated with an enzyme substrate. A method of detecting a target in a test sample includes exposing the test sample to the probe, then treating the test sample with an enhancement or development solution to deposit at least one of a fluorophore, a chromogen, or a metal.

Abstract: A determination method quantifies a specific protein or peptide contained in a trace amount with high accuracy and in a simple manner without the need of using any expensive reagent. A protein or peptide of interest can be quantified by LC/MS/MS by using, as an internal standard, a protein or peptide including an amino acid sequence having the reshuffling the binding order of amino acid residues in the amino acid sequence for the protein or peptide of interest.

Abstract: An assay method and device can perform at least one (e.g., at least two) assays on a single aliquot of a sample liquid. The device can mix a sample liquid with assay reagents including magnetically susceptible particles. The device is configured to create a sample liquid-air interface with the sample liquid. The magnetically susceptible particles can be located (via an applied magnetic field) at the liquid-air interface when a second liquid contacts the interface to form a liquid-liquid interface. The magnetic particles travel across the liquid:liquid interface to the second liquid. The magnetically susceptible particles are configured to transport an analyte across the interface into the second liquid. An assay for the analyte is performed in the second liquid. An assay for another analyte can also be performed in the sample liquid.

Abstract: It was able to provide a method for carrying out an enzyme immunoassay such as ELISA or sandwich ELISA, which hardly inhibited by antiseptics and has high reactivity and sensitivity similar or superior to the performance in the case of the use of an antibody labeled using POD derived from horseradish, by carrying out the enzyme immunoassay by labeling a POD derived from Basidiomycetes and using the labeled antibody under an immobilized state. Additionally, even when antiseptics including sodium azide are added, the POD activity is hardly inhibited so that it was able to carry out the enzyme immunoassay with good reactivity and sensitivity.

Abstract: The present invention relates to a method for detecting a viable microorganism in a pharmaceutical composition comprising the steps of providing a filterable pharmaceutical composition; filtering the pharmaceutical composition to provide at least three membranes upon which the pharmaceutical composition is deposited, placing the three membranes onto solid culture media to produce at least three filtrand cultures, culturing under aerobic and anaerobic conditions and detecting a viable microorganism cell, micro-colony or colony, wherein the presence of a viable cell, micro-colony or colony on the membrane indicates the presence of a viable microorganism in the pharmaceutical composition.

Abstract: This document relates to methods and materials involved in diagnosing sleep apnea and assessing the effectiveness of a treatment for sleep apnea. For example, methods and materials for using markers to determine whether or not a mammal (e.g., a human) has sleep apnea are provided. In addition, methods and materials that can be used to determine whether or not a mammal (e.g., a human) responds to a sleep apnea treatment are provided.

Abstract: Latently detectable tracers for use in fluid conducting and containment systems wherein the interaction between the tracer and a biomacromolecule produces a detectable signal. More specifically, the latently detectable tracers monitor flow through such systems. Methods for monitoring the flow of fluid using the tracers, and a kit for use in monitoring the flow of fluid in such systems, including the tracers are also disclosed.